{"public_id":"cl_dcd8097e24919efd1a750413e248da6a","status":"active","superseded_by_public_id":null,"corpus_id":26614083,"text":"Current knowledge about amorphous character is applied to pharmaceutical formulation problems.","confidence":0.86,"paper":{"corpus_id":26614083,"title":"Characteristics and significance of the amorphous state in pharmaceutical systems.","url":"https://sah.borca.ai/papers/26614083"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.86,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_4c14f7cf72e025e45cf12584ed801914","name":"pharmaceutical formulation problems","description":"Challenges involved in designing and preparing pharmaceutical formulations.","types":["problem"],"url":"https://sah.borca.ai/concepts/co_4c14f7cf72e025e45cf12584ed801914"},{"public_id":"co_5322cfc36c7f18951d59e68753ee4f7d","name":"amorphous character","description":"The extent or presence of amorphous nature in a pharmaceutical system.","types":["property"],"url":"https://sah.borca.ai/concepts/co_5322cfc36c7f18951d59e68753ee4f7d"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_dcd8097e24919efd1a750413e248da6a"}